News and Investors

Watch how we are developing glass microsphere technologies to treat cancer

Latest News

December 6th 2022

ABK Biomedical Raises USD 30M in Series C Funding

Go to the Press Release»»

September 12th 2022

ABK Biomedical announces FDA 510(k) clearance of Easi-Vue™ embolic microspheres for the embolization of arteriovenous malformations and hypervascular tumors

Go to the Press Release»»

September 12th 2022

ABK Biomedical announces the appointment of Dr. Aravind Arepally as Chief Medical Officer effective, September 12th 2022

Meet Our New CMO»»

April 19th 2022

ABK Biomedical Announces First Patient Treated in First-in-Human Clinical Study with Eye90 microspheres™ for treatment of liver tumors

Go to the Press Release»»

Meet Our New CMO

ABK Biomedical announces the appointment of Dr. Aravind Arepally to the newly created full-time position of Chief Medical Officer effective, September 12th, 2022.

Aravind joins ABK with extensive clinical experience in Interventional Oncology, Y90 procedures, and the medical device industry. Aravind obtained his medical degree and completed his radiology residency at Emory University in Atlanta. After finishing his fellowship at Johns Hopkins Medical Institutes, he joined the faculty, becoming an Associate Professor of Radiology and Surgery. Aravind eventually moved back to Atlanta as a practicing physician in private practice, becoming the Chair of Radiology, Section Chief of IR, and a member of the Board of Directors at Radiology Associates of Atlanta at Piedmont Hospital. He is also currently an Adjunct Professor of Radiology at Vanderbilt University School of Medicine.

In the area of medical technology development, Aravind co-founded Surefire Medical in 2010 where he was Chief Scientific Officer and spent 10 years guiding pre-clinical research, global clinical trials/strategy, and FDA interactions. Surefire (now TriSalus Life Sciences) is now commercially available in US, Europe, Asia, and South America. Additional prior industry experience includes time as a Visiting Clinical Scientist with Siemen’s Healthcare focusing on molecular imaging and image guided therapies. Most recently, Aravind left full-time clinical practice and was appointed Senior Director of R&D for Varian, Siemens Healthineers.

Aravind has received numerous NIH Grants and completed several human clinical trials in the areas of Imaging, Medical Devices, and embolotherapies. He is an author on over 150 publications, numerous medical textbooks, and has been part of faculty and lectures at over 100 conferences in his career. He has extensive teaching and mentoring experience and has consulted for many companies in the Interventional Radiology and Oncology space. He is a widely respected Key Opinion Leader in Interventional Medicine and has performed over 500 Yttrium 90 procedures in his career. His unique combination of industry, start-up, imaging, radiology, and oncology experience make him uniquely suited as the Chief Medical Officer at ABK Biomedical Inc.

 

Aravind Arepally, MD., Chief Medical Officer

Company News & Press Releases

ABK and University of Missouri Veterinary Health Center partner on new liver cancer trial for dogs

Halifax, Nova Scotia. March 7th, 2021. ABK Biomedical today announced that they entered into a partnership with…

Read about the study»»

ABK Biomedical partners with the CNIC to enhance patient care

Halifax, Nova Scotia. March 3rd 2020. ABK Biomedical, which is developing a transformative Eye90 microspheres® technology, with the potential to provide in-procedure prognostic dosimetry

Read the Press Release»»

ABK Biomedical Inc. Raises $30M USD in Series B Financing

Halifax, Nova Scotia. April 8th, 2019. ABK Biomedical, Inc., a medical device company dedicated to the research, development and commercialization of innovative embolic therapies, announced a $30 million USD Series B financing…

Read the Press Release»»

Strategic Partnership with the University of Missouri Research Reactor Center (MURR®)

Halifax, Nova Scotia. February 13th, 2019. ABK Biomedical Inc. (ABK) is pleased to announce a multi-year strategic partnership with the University of Missouri Research Reactor Center (MURR®)…

Read the Press Release»»

In The News

Bland embolization with easi-vue embolic microspheres

Easi-Vue™ embolic microspheres featured in Design News September 2022

 

Design News recently profiled the important 510(k) clearance for Easi-Vue embolic microspheres.

Chief Business Officer, Gary Donofrio, and VP of manufacturing Anthony Headley provided ABK Biomedical’s perspective on the importance of this achievement, and on the impact this see-and-do technology may have on patient treatment practices.

Click here to read the article.

Eye90 microspheres Precision Dosimetry™ profiled in Physics World July 2022

 

MD Anderson Cancer Center post-doctoral fellow and ABK-affiliated researcher Dr. E Courtney Henry presented on recent advances in Y90 dosimetry at the 2022 American Association of Physicists in Medicine annual meeting.

The association recognized this research as a “Best in Physics” presentation. Click here to read more about this important advance and its impact on Y90 technology.

 

Precision Dosimetry

 

ABK Chief Medical Officer interviewed by Interventional News

 

Bob Abraham, MD, CMO at ABK Biomedical was interviewed by Interventional News in 2020 at The SPECTRUM Conference. Dr Abraham discussed the potential of using CT imaging with ABK Biomedical’s radiopaque microspheres to precisely map absorbed radiation dose.

Click the image for Dr Abraham’s perspective on this exciting advance in microsphere technology.

Co-Founder Discusses ABK’s Unique Microsphere Technology

 

ABK Biomedical Co-founder, Dr. Daniel Boyd, outlines the history of ABK, and the novel glass microsphere technologies the company is developing. 

ABK's Business Partners

ABK Biomedical is proud to partner with cutting-edge organizations and individuals with exceptional skills, scientific expertise, and the highest business ethics.

Research Partners

Development Partners

MORE THAN JUST AN EMPLOYER

The ABK Biomedical Team

We are dedicated to encouraging a stimulating work environment offering an opportunity to significantly expand experience and skills by researching, developing, and commercializing cutting-edge medical device technologies with a mandate to effectively treat cancer.

ABK Biomedical is an equal opportunity employer offering competitive compensation packages.

Corporate Offices

Halifax Office (Main Office)
155 Chain Lake Drive
Unit 32
Halifax, NS B3S 1B3
Canada

T. 902.442.4009

 

Orange County Office
555 Corporate Drive 
Suite 105
Ladera Ranch, CA, 92694
USA

ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for the accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical Inc. may change the products mentioned, and their stage in development, at any time without notice. ABK Biomedical Inc. is a clinical-stage company engaged in the research and development of new medical devices. Eye90 microspheres® is considered an investigational product and is NOT FDA-approved for use.

Copyright 2022 - All International Rights Reserved